Global Radiation Oncology Market
Global Radiation Oncology Market Report 2023: Demand for Advanced Cancer Treatment Options Fuels Growth
June 06, 2023 05:28 ET | Research and Markets
Dublin, June 06, 2023 (GLOBE NEWSWIRE) -- The "Global Radiation Oncology Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global radiation...
PDS Biotech Logo.png
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
May 25, 2023 17:00 ET | PDS Biotechnology Corporation
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control...
PDS Biotech Logo.png
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results
May 15, 2023 07:30 ET | PDS Biotechnology Corporation
Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE...
PDS Biotech Logo.png
PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients
April 27, 2023 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
invios-Logo-RGB-small.jpg
invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
April 18, 2023 09:00 ET | invIOs GmbH
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver...
PDS Biotech Logo.png
PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023
April 03, 2023 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023
March 30, 2023 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium 
March 29, 2023 07:30 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted...
PDS Biotech Logo.png
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results
March 28, 2023 07:30 ET | PDS Biotechnology Corporation
Successful meeting with FDA to discuss registrational pathway for triple combination of PDS0101, PDS0301, and a commercial immune checkpoint inhibitor100% (9/9) clinical response (>60% tumor...
proton-therapy-market-size.jpg
The Worldwide Proton Therapy Industry is Expected to Reach $963.6 Million by 2028
January 12, 2023 04:43 ET | Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "Global Proton Therapy Market Size, Share & Industry Trends Analysis Report By Product Type, By Indication (CNS Cancer, Prostate Cancer, Head &...